| Market Capitalization (Millions $) |
5,952 |
| Shares
Outstanding (Millions) |
100 |
| Employees |
370 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-409 |
| Cash Flow (TTM) (Millions $) |
410 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Xenon Pharmaceuticals Inc is a Canadian biopharmaceutical company that specializes in the discovery and development of novel therapies for neurological disorders. The company focuses on targeting ion channels, which are proteins involved in electrical signaling within the nervous system. Xenon utilizes a proprietary drug discovery platform called Extreme Genetics® to identify rare mutations in genes that are associated with particular diseases. This approach allows the company to develop precision medicines tailored to specific patient populations. Xenon is engaged in various clinical programs targeting conditions such as epilepsy, migraine, and neurologic channelopathies. As of now, Xenon's pipeline includes both early-stage investigational drugs and those in advanced stages of clinical development.
Company Address: 3650 Gilmore Way Burnaby 0 BC
Company Phone Number: 484-3300 Stock Exchange / Ticker: NASDAQ XENE
|
0.36% 